Skip Navigation

European Heart Journal 1994 15(Supplement D):139-144; doi:10.1093/eurheartj/15.suppl_D.139
Copyright © 1994 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sweet, C. S.
Right arrow Articles by Rucinska, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sweet, C. S.
Right arrow Articles by Rucinska, E. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 The European Society of Cardiology

Losartan in Heart Failure: Preclinical Experiences and Initial Clinical Outcomes

C. S. Sweet and E. J. Rucinska

Merck Research Laboratories, Clinical Cardiovascular Resenrch West Point, PA, U.S.A.

Correspondence: C. S. Sweet, Merck Research Laboratories, Clinical Cardiovascular Rcscarch, West Point, PA 19486, U.S.A.

Losartan potassium (Cozaar®) is an angiotensin II receptor antagonist (AT1 selective) which has undergone extensive clinical trials for the treatment of hypertension.

This literature survey will review some of the pre-clinical findings with losortan in models of heart failure, and where appropriate, we will compare the haemodynamic findings in animals with similar studies completed in patients The major conclusion from these trials is that losartan has clear haemodynamic benefits in patients in heart failure and that the drug appears to be well tolerated, with a low incidence of adverse experiences related to impaired renal function.

Key Words: Angiotensin II antagonists • losartan • heart failure • renal function


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.